Announcement • Jul 28
BiBBInstruments AB Receives Intention To Grant For Fourth And Fifth EndoDrill Patent In Europe And Is Granted Second Patent In India BiBBInstruments AB announced that the Company has received two Intentions to Grant from the European Patent Office (EPO) as well as a patent grant from the Indian Patent Office (IPO). The European patents will be granted following the completion of certain formalities, after which they will be valid until 2040 and 2041, respectively. The patent in India is valid until 2041. The protection is based on three international EndoDrill patent families with granted patents in Europe, the United States, Japan, India and China. The two Intention to Grant in Europe relate to patent applications No. 20719144.6 and 21716219.7 respectively. These patents belong to BiBB's second and third EndoDrill patent families and provide additional protection for the Company's powered biopsy technology in Europe. Previously, BiBB has been granted three patents in Europe that are valid until 2038 and 2039, and the new patents will extend the protection until 2040 and 2041, respectively. The second granted patent in India (No. 596371) belongs to BiBB's third EndoDrill patent family and provides robust protection for the Company's powered biopsy technology in India. The first granted patent is valid until 2039, while this patent will be valid until 2041. EndoDrill is designed to obtain core needle biopsy (CNB) samples with high diagnostic accuracy and aims to improve the diagnosis of cancer in, among other organs, the stomach, pancreas, liver, lungs and urinary bladder. The product portfolio addresses the global market for ultrasound-guided endoscopic biopsy instruments (EUS/EBUS), one of the most advanced and fastest-growing segments within modern endoscopy. BiBB received FDA 510(k) clearance for EndoDrill GI in 2023 and CE marking under the MDR for EndoDrill GI, EndoDrill EBUS and EndoDrill URO in 2024. EndoDrill is therefore the first powered biopsy system to be market-cleared in the United States and CE-marked in Europe. The U.S. launch of EndoDrill GI commenced during the second half of 2025 together with TaeWoong Medical USA. The European launch begins in 2026 with the Company's partner, Palex Medical Spain. The EndoDrill system consists of sterile single-use instruments and a proprietary drive system. Announcement • Jul 23
BiBBInstruments AB to Report Q2, 2026 Results on Aug 21, 2026 BiBBInstruments AB announced that they will report Q2, 2026 results on Aug 21, 2026 Board Change • Jul 07
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Director Sara Lindroth was the last independent director to join the board, commencing their role in 2018. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 
